Success in systemic immunotherapy against metastatic cancer hinges on the ability to achieve tumour-specific immune activation over normal tissues. Single-gate stimuli-responsive systems are not adequate at differentiating tumour versus normal tissue signals. ... ...

请注册登录后继续浏览